Partial Seizures
Conditions
Keywords
Epilepsy, Partial Seizures, Levetiracetam, Monotherapy, Adjunctive Treatment
Brief summary
This is a study to confirm the efficacy of levetiracetam as adjunctive treatment or as monotherapy in pediatric epilepsy subjects aged 1 month to less than 4 years of age with partial seizures.
Detailed description
The study will consist of 2 periods. The First Period (6 weeks drug treatment) is designed to confirm efficacy of levetiracetam (LEV), and the Second Period is designed to evaluate the long-term efficacy and safety of LEV.
Interventions
DRUGLevetiracetam
levetiracetam dry syrup 50% for oral administration and levetiracetam solution for infusion (100 mg/mL)
Sponsors
UCB Japan Co. Ltd.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Months to 3 Years
Healthy volunteers
No
Inclusion criteria
* Subject must have a diagnosis of epilepsy with partial onset seizures whether or not secondarily generalized * Male or female from 1 month to \<4 years of age. Pre-term infants aged \<1 year are to be stratified into an appropriate age category using the best estimate of their corrected gestational age * For subjects on adjunctive therapy, subject must be on a stable antiepileptic drug (AED) regimen for the Selection and Evaluation Periods of the study. Minor adjustments to the dose of current AEDs are allowed only prior to Visit 1. Monotherapy subjects must not receive AED treatment, receive temporary AED treatment, or switch an AED prior to Visit 1 * Subject weighs \>=3.0 kg * Subject may have Vagal Nerve Stimulation (VNS) which has been implanted for at least 6 months prior to Visit 1; the settings must be stable for at least 2 months prior to Visit 1. Activated VNS must be counted as 1 of the 2 AEDs * Subject must have experienced at least 2 observable partial seizures, with or without secondary generalization during each 7-day period during the 2 weeks prior to Visit 1. This time period (the 2 weeks prior to Visit 1) will be referred to as the Retrospective Baseline Period. This seizure information (including type, frequency, and date) must have been recorded on a daily record card (DRC) in order to be acceptable * If epilepsy surgery has been performed prior to study entry, subjects must have a documented failed epilepsy surgery outcome at least 4 weeks prior to Visit 1 * The use of intermittent benzodiazepines, phenobarbitals, and phenytoins is allowed as long as the frequency is not greater than 1 single administration per week for at least 2 weeks prior to Visit 1 and throughout study participation. If benzodiazepines are used more than once a week, they must be considered as 1 of the AEDs
Exclusion criteria
* Subject has been taking any medication (other than their concomitant AEDs) that influences the central nervous system (CNS) for which they had not been on a stable regimen for at least 1 month prior to Visit 1 * Subject is taking any medication that may interfere with the absorption, distribution, metabolism, or excretion of the concomitant AEDs or levetiracetam (LEV) during the course of the study * Subject has received any investigational medication or device within 30 days prior to Visit 1 * Subject has taken LEV prior to the study * Subjects using felbamate who have presented with clinically significant abnormalities and/or hepatic function during felbamate treatment, and subjects who are taking felbamate \<1year from the date of Visit 1 * History of status epilepticus requiring hospitalization during the 30 days prior to Visit 1, except for status epilepticus occurring during the first 10 days of life * Subject has a treatable seizure etiology * Subject is on a ketogenic diet (concomitantly or within 30 days prior to Visit 1) * Subject has epilepsy secondary to progressing cerebral diseases * Subject has a current diagnosis of Rasmussen's syndrome, Landau-Kleffner disease or Lennox-Gastaut syndrome * Clinically significant deviations from reference range values for renal function or any of the other laboratory parameters required for this study, as determined by the Investigator * Clinically significant acute or chronic illness (as determined during the physical examination or from other information available to the Investigator) * Allergy to pyrrolidine derivatives or a history of multiple drug allergies * Subject is known to have a terminal illness * Subject has a disorder or condition that may interfere with the absorption, distribution, metabolism, or excretion of medications * Subject has a history of or presence of pseudoseizures * Subject has any medical condition that might interfere with the subject's study participation * Subject has ≥3x upper limit of normal (ULN) of any of the following: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or \>ULN total bilirubin (≥1.5xULN total bilirubin if known Gilbert's syndrome). If subject has elevations only in total bilirubin that are \>ULN and \<1.5xULN, fractionate bilirubin to identify possible undiagnosed Gilbert's syndrome (ie, direct bilirubin \<35%)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6 | From Baseline (Week 0) to Visit 6 (up to Week 6) | The percent difference in partial seizure frequency per week at Baseline and Study Visit 6 (Week 6) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 6)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 5 | From Baseline (Week 0) to Visit 5 (up to Week 4) | The percent difference in partial seizure frequency per week at Baseline and Study Visit 5 (Week 4) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 5)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy. |
| Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | From Baseline (Week 0), Week 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV (up to Week 295), and Safety follow-up (up to Week 295) | Percent difference in partial seizure frequency (PSF) per week at each Analysis Visit: {\[(Number of partial seizures per week at Baseline \[BL\]) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Positive value indicates reduction in PSF from BL. End of study (EOS)/early discontinuation visit (EDV) was based on last EDV and calculation of number of partial seizure per week were based on the period from the previous EDV visit. The mapping of seizure data to Analysis Visits was based on target dates of the visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to the next Analysis Visit (n+1). Data for one participant assessed within study duration was mapped to Analysis Visit 35/Week 300 based on statistical plan. |
| Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV Week 2, EOS/EDV Week 4, and Safety follow-up (up to Week 295) | Percent difference in PSF per week on adjunctive therapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PSF per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. Positive value in percent difference from Baseline indicates reduction in PSF from Baseline. The mapping of seizure data to Analysis Visits was based on target dates of visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to next Analysis Visit (n+1). |
| Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295) | The percent difference in partial seizure frequency per week on monotherapy at Baseline and each analysis visit was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at analysis visit X)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. The maximum duration of study participation in monotherapy participants was shorter than in adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy. |
| Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295) | Percent difference in PSF per week on monotherapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PFS per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. Maximum duration of study participation in monotherapy participants was shorter than adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy. |
| Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 4 | From Baseline (Week 0) to Visit 4 (up to Week 2) | The percent difference in partial seizure frequency per week at Baseline and Study Visit 4 (Week 2) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 4)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy. |
| Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period | From Baseline (Week 0) to Visit 6 (up to Week 6) | A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. |
| Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period | From Baseline (Week 0) to Visit 6 (up to Week 6) | An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported. |
| Percentage of Participants With TEAEs During the Combined First and Second Period | From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295) | An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. |
| Percentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period | From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295) | A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. |
| Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period | From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295) | An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported. |
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period | From Baseline (Week 0) to Visit 6 (up to Week 6) | An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation Participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The treatment-emergent adverse events (TEAEs) were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. |
Countries
Japan
Participant flow
Recruitment details
The study started to enroll participants in November 2017 and concluded in July 2023.
Pre-assignment details
Participant Flow refers to the Safety Set Adjunctive therapy (SS\_A) and Safety Set Monotherapy (SS\_M).
Participants by arm
| Arm | Count |
|---|---|
| Levetiracetam: Adjunctive Therapy Participants aged 1 month to less than (\<) 6 months received Levetiracetam (LEV) 14 milligram per kilogram per day (mg/kg/day) as adjunctive therapy at Visit 3 (Week 0) of First Period and dose up titrated up to 42 mg/kg/day. Participants aged 6 months to \<4 years received LEV 20 mg/kg/day at Visit 3 (Week 0) of first period and dose up titrated up to a maximum of 60 mg/kg/day up to 6 weeks. The dose was increased by 2 weeks interval as per Investigator's discretion. At Visit 6 (Week 6), dose of participants either down-titrated during 4 weeks interval or they entered in second period and continued LEV 14 to 42 mg/kg/day in participants aged 1 month to \<6 months or LEV 20 to 60 mg/kg/day for participants aged greater than or equal to (≥) 6 months \<4 years at the discretion of the Investigator. Participants visited every 4 weeks for the first 6 months of administration and then every 12 weeks thereafter until approval or till program discontinued. The dose down-titrated during 4 weeks Interval at the discretion of Investigator. | 32 |
| Levetiracetam: Monotherapy Participants aged 1 month to \< 6 months received LEV 14 mg/kg/day as monotherapy at Visit 3 (Week 0) of First Period and dose up titrated up to 42 mg/kg/day. Participants aged 6 months to \<4 years received LEV 20 mg/kg/day at Visit 3 (Week 0) of first period and dose up titrated up to a maximum of 60 mg/kg/day up to 6 weeks. The dose was increased by 2 weeks interval as per Investigator's discretion. At Visit 6 (Week 6), dose of participants either down-titrated during 4 weeks interval or they entered in second period and continued LEV 14 to 42 mg/kg/day in participants aged 1 month to \<6 months or LEV 20 to 60 mg/kg/day for participants aged ≥ 6 months \<4 years at the discretion of the Investigator. Participants visited every 4 weeks for the first 6 months of administration and then every 12 weeks thereafter until approval or till the program discontinued. The dose could be down-titrated during 4 weeks Interval at the discretion of Investigator. | 6 |
| Total | 38 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| First Period | Adverse Event, non-fatal | 2 | 0 |
| First Period | Lack of Efficacy | 3 | 0 |
| Second Period | Adverse Event, non-fatal | 1 | 1 |
| Second Period | Approved Drug Available For Indication | 1 | 0 |
| Second Period | Lack of Efficacy | 11 | 0 |
| Second Period | Physician Decision | 3 | 0 |
| Second Period | Protocol-Specified Withdrawal Criterion Met | 1 | 0 |
| Second Period | Withdrawal by Subject | 2 | 1 |
Baseline characteristics
| Characteristic | Levetiracetam: Adjunctive Therapy | Levetiracetam: Monotherapy | Total |
|---|---|---|---|
| Age, Continuous | 14.7 Years STANDARD_DEVIATION 10.7 | 32.4 Years STANDARD_DEVIATION 13.2 | 17.5 Years STANDARD_DEVIATION 12.7 |
| Age, Customized 24 months - <12 years | 6 Participants | 3 Participants | 9 Participants |
| Age, Customized 28 days - <24 months | 26 Participants | 3 Participants | 29 Participants |
| Race/Ethnicity, Customized Asian | 32 Participants | 6 Participants | 38 Participants |
| Race/Ethnicity, Customized Japan | 32 Participants | 6 Participants | 38 Participants |
| Sex: Female, Male Female | 15 Participants | 5 Participants | 20 Participants |
| Sex: Female, Male Male | 17 Participants | 1 Participants | 18 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 32 | 0 / 6 |
| other Total, other adverse events | 28 / 32 | 6 / 6 |
| serious Total, serious adverse events | 18 / 32 | 2 / 6 |
Outcome results
Primary
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6
The percent difference in partial seizure frequency per week at Baseline and Study Visit 6 (Week 6) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 6)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.
Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)
Population: The Full Analysis Set Adjunctive therapy (FAS\_A) consisted of all participants in the SS\_A who had at least 1 post-Baseline efficacy assessment. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 6 | 24.24 percent change |
Secondary
Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy
Percent difference in PSF per week on adjunctive therapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PSF per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. Positive value in percent difference from Baseline indicates reduction in PSF from Baseline. The mapping of seizure data to Analysis Visits was based on target dates of visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to next Analysis Visit (n+1).
Time frame: From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV Week 2, EOS/EDV Week 4, and Safety follow-up (up to Week 295)
Population: FAS\_A consisted of all participants in SS\_A who had at least 1 post-Baseline efficacy assessment. Here, number analyzed signifies participants who were at risk at each previous analysis visit (X-1). As per planned analysis, outcome categories ≥50%, ≥75% and 100% are overlapping, so that percentages of categories of this outcome measure can add up to more than 100%. Data for one participant assessed within study duration was mapped to Analysis Visit 35/Week 300 based on statistical plan.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 2: 0% - <25% | 18.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 2: 25% - <50% | 9.4 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 2: ≥ 75% | 12.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 4: <0% | 37.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 4: 0% - <25% | 18.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 4: 25% - <50% | 15.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 4: ≥ 75% | 18.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 2: ≥ 50% | 28.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 2: 100% | 9.4 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 4: ≥ 50% | 28.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 6: 25% - <50% | 12.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 6: ≥ 50% | 28.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 8: 0% - <25% | 14.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 8: 25% - <50% | 17.9 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 8: 100% | 17.9 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 10: 25% - <50% | 8.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 12: <0% | 20.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 12: ≥ 75% | 37.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 12: 100% | 25.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 15: 25% - <50% | 13.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 15: ≥ 50% | 63.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 21: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 72: ≥ 75% | 76.9 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 96: ≥ 75% | 92.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 168: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 216: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 276: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 276: 100% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 288: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 2: <0% | 43.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 60: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 60: 25% - <50% | 6.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 60: ≥ 50% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 60: ≥ 75% | 68.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 60: 100% | 43.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 72: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 72: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 72: 25% - <50% | 7.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 72: ≥ 50% | 92.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 72: 100% | 53.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 84: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 84: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 84: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 84: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 84: ≥ 75% | 84.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 84: 100% | 53.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 96: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 96: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 96: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 96: ≥ 50% | 92.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 96: 100% | 46.2 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 108: <0% | 8.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 108: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 108: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 108: ≥ 50% | 83.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 108: ≥ 75% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 108: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 120: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 120: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 120: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 120: ≥ 50% | 90.9 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 120: ≥ 75% | 90.9 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 120: 100% | 63.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 132: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 132: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 132: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 132: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 132: ≥ 75% | 70.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 132: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 144: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 144: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 144: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 144: ≥ 50% | 87.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 144: ≥ 75% | 87.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 144: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 156: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 156: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 156: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 156: ≥ 50% | 85.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 156: ≥ 75% | 85.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 156: 100% | 42.9 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 168: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 168: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 168: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 168: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 168: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 180: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 180: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 180: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 180: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 180: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 180: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 192: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 192: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 192: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 192: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 192: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 192: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 204: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 204: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 204: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 204: ≥ 50% | 83.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 204: ≥ 75% | 83.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 204: 100% | 16.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 216: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 216: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 216: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 216: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 216: 100% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 228: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 228: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 228: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 228: ≥ 50% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 228: ≥ 75% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 228: 100% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 240: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 240: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 240: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 240: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 240: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 240: 100% | 33.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 252: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 252: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 252: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 252: ≥ 50% | 66.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 252: ≥ 75% | 66.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 252: 100% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 264: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 264: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 264: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 264: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 264: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 264: 100% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 276: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 276: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 276: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 276: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 288: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 288: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 288: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 288: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 288: 100% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 300: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 300: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 300: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 300: ≥ 50% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 300: ≥ 75% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 300: 100% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 2: <0% | 3.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 2: 0% - <25% | 3.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 2: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 2: ≥ 50% | 3.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 2: ≥ 75% | 3.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 2: 100% | 3.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 4: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 4: 0% - <25% | 10.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 4: 25% - <50% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 4: ≥ 50% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 4: ≥ 75% | 10.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | EOS/EDV, Week 4: 100% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Safety Follow Up: <0% | 37.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Safety Follow Up: 0% - <25% | 4.2 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Safety Follow Up: 25% - <50% | 12.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Safety Follow Up: ≥ 50% | 45.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Safety Follow Up: ≥ 75% | 29.2 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Safety Follow Up: 100% | 20.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 4: 100% | 9.4 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 6: <0% | 31.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 6: 0% - <25% | 15.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 6: ≥ 75% | 18.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 6: 100% | 15.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 8: <0% | 21.4 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 8: ≥ 50% | 35.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 8: ≥ 75% | 25.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 10: <0% | 24.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 10: 0% - <25% | 12.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 10: ≥ 50% | 52.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 10: ≥ 75% | 28.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 10: 100% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 12: 0% - <25% | 4.2 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 12: 25% - <50% | 20.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 12: ≥ 50% | 45.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 15: <0% | 13.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 15: 0% - <25% | 9.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 15: ≥ 75% | 36.4 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 15: 100% | 27.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 18: <0% | 9.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 18: 0% - <25% | 4.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 18: 25% - <50% | 9.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 18: ≥ 50% | 68.2 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 18: ≥ 75% | 54.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 18: 100% | 31.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 21: <0% | 10.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 21: 0% - <25% | 5.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 21: 25% - <50% | 5.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 21: ≥ 75% | 55.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 21: 100% | 30.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 24: <0% | 10.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 24: 0% - <25% | 10.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 24: 25% - <50% | 5.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 24: ≥ 50% | 70.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 24: ≥ 75% | 55.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 24: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 27: <0% | 5.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 27: 0% - <25% | 5.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 27: 25% - <50% | 10.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 27: ≥ 50% | 73.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 27: ≥ 75% | 52.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 27: 100% | 36.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 30: <0% | 5.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 30: 0% - <25% | 11.1 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 30: 25% - <50% | 5.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 30: ≥ 50% | 72.2 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 30: ≥ 75% | 55.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 30: 100% | 44.4 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 36: <0% | 11.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 36: 0% - <25% | 5.9 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 36: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 36: ≥ 50% | 76.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 36: ≥ 75% | 70.6 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 36: 100% | 52.9 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 48: <0% | 6.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 48: 0% - <25% | 12.5 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 48: 25% - <50% | 6.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 48: ≥ 50% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 48: ≥ 75% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 48:100% | 43.8 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Adjunctive Therapy | Week 60: <0% | 0 percentage of participants |
Secondary
Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy
Percent difference in PSF per week on monotherapy at BL and each analysis visit: {\[(Number of partial seizures per week at BL) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Percent difference in PFS per week from Baseline for each participant and analysis visit were mapped into 6 categories: \<0%, 0% to \<25%, 25% to \<50%, ≥50%, ≥75%, and 100%, then percentages of participants in these categories were derived using the number of participants at risk at each previous analysis visit as denominator. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. Maximum duration of study participation in monotherapy participants was shorter than adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.
Time frame: From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295)
Population: The FAS\_M consisted of all participants in the SS\_M who had at least 1 post-Baseline efficacy assessment. Here, number analyzed signifies participants who were at risk at each previous analysis visit (X-1). As per planned analysis, outcome categories ≥50%, ≥75% and 100% are overlapping, so that percentages of categories of this outcome measure can add up to more than 100%.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 2: <0% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 2: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 2: 25% - <50% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 2: ≥ 50% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 2: ≥ 75% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 2: 100% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 4: <0% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 4: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 4: 25% - <50% | 16.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 4: ≥ 50% | 33.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 4: ≥ 75% | 33.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 4: 100% | 33.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 6: <0% | 33.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 6: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 6: 25% - <50% | 16.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 6: ≥ 50% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 6: ≥ 75% | 33.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 6: 100% | 16.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 8: <0% | 16.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 8: 0% - <25% | 16.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 8: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 8: ≥ 50% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 8: ≥ 75% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 8: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 10: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 10: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 10: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 10: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 10: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 10: 100% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 12: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 12: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 12: ≥ 50% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 12: ≥ 75% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 12: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 15: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 15: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 15: 25% - <50% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 15: ≥ 50% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 15: ≥ 75% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 15: 100% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 18: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 18: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 18: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 18: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 18: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 18: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 21: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 21: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 21: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 12: 25% - <50% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 21: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 48: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 156: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 168: <0% | 25.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 168: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 168: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 168: 100% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 180: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 180: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 192: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 228: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 228: ≥ 75% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 228: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 264: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 27: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 27: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 27: 25% - <50% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 27: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 27: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 27: 100% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 30: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 21: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 72: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 21: 100% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 24: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 24: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 24: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 24: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 24: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 24: 100% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 30: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 72: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 96: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 96: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 96: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 108: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 108: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 108: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 108: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 108: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 108: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 120: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 120: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 120: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 120: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 120: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 120: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 132: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 132: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 132: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 132: ≥ 50% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 132: ≥ 75% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 132: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 144: <0% | 25.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 144: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 144: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 144: ≥ 50% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 144: ≥ 75% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 144: 100% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 156: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 156: 0% - <25% | 25.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 156: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 156: ≥ 50% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 156: ≥ 75% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 72: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 72: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 84: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 84: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 84: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 84: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 84: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 30: 25% - <50% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 30: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 84: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 96: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 96: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 30: ≥ 75% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 30: 100% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 96: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 36: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 36: 0% - <25% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 36: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 36: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 36: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 36: 100% | 60.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 48: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 48: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 48: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 48: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 48:100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 60: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 60: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 60: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 60: ≥ 50% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 60: ≥ 75% | 80.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 60: 100% | 40.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 72: <0% | 20.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 72: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 168: ≥ 50% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 168: ≥ 75% | 75.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 180: <0% | 25.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 180: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 180: ≥ 50% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 180: ≥ 75% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 192: <0% | 33.3 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 192: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 192: ≥ 50% | 66.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 192: ≥ 75% | 66.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 192: 100% | 66.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 204: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 204: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 204: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 204: ≥ 50% | 66.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 204: ≥ 75% | 66.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 204: 100% | 66.7 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 216: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 216: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 216: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 216: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 216: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 216: 100% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 228: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 228: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 228: ≥ 50% | 50.0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 240: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 240: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 240: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 240: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 240: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 240: 100% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 252: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 252: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 252: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 252: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 252: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 252: 100% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 264: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 264: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 264: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 264: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 264: 100% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 276: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 276: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 276: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 276: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 276: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Week 276: 100% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Safety Follow Up: <0% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Safety Follow Up: 0% - <25% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Safety Follow Up: 25% - <50% | 0 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Safety Follow Up: ≥ 50% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Safety Follow Up: ≥ 75% | 100 percentage of participants |
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With a Percent Change in Partial Seizure Frequency Per Week of <0%, 0% to <25%, 25% to <50%, ≥50%, ≥75%, or 100% on Monotherapy | Safety Follow Up: 100% | 100 percentage of participants |
Secondary
Percentage of Participants With TEAEs During the Combined First and Second Period
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
Time frame: From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)
Population: The SS\_A consisted of all enrolled participants on adjunctive therapy who received at least 1 dose of study medication in the evaluation period. The SS\_M consisted of all enrolled participants on monotherapy who received at least 1 dose of study medication in the evaluation period.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With TEAEs During the Combined First and Second Period | 96.9 percentage of participants |
| Levetiracetam: Monotherapy | Percentage of Participants With TEAEs During the Combined First and Second Period | 100 percentage of participants |
Secondary
Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.
Time frame: From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)
Population: The SS\_A consisted of all enrolled participants on adjunctive therapy who received at least 1 dose of study medication in the evaluation period. The SS\_M consisted of all enrolled participants on monotherapy who received at least 1 dose of study medication in the evaluation period.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period | 9.4 percentage of participants |
| Levetiracetam: Monotherapy | Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the Combined First and Second Period | 16.7 percentage of participants |
Secondary
Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period
An AE is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication. TEAEs leading to discontinuation from study medication are reported.
Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)
Population: The SS\_A consisted of all enrolled participants on adjunctive therapy who received at least 1 dose of study medication in the evaluation period. The SS\_M consisted of all enrolled participants on monotherapy who received at least 1 dose of study medication in the evaluation period.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period | 6.3 percentage of participants |
| Levetiracetam: Monotherapy | Percentage of Participants With TEAEs Leading to Discontinuation From Study Medication During the First Period | 0 percentage of participants |
Secondary
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation Participant administered a pharmaceutical product that does not necessarily have a causal relationship treatment. An AE could therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. The treatment-emergent adverse events (TEAEs) were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)
Population: The SS\_A consisted of all enrolled participants on adjunctive therapy who received at least 1 dose of study medication in the evaluation period. The SS\_M consisted of all enrolled participants on monotherapy who received at least 1 dose of study medication in the evaluation period.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period | 62.5 percentage of participants |
| Levetiracetam: Monotherapy | Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the First Period | 0 percentage of participants |
Secondary
Percentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period
A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
Time frame: From Baseline (Week 0) to the End of Safety Follow-up (up to Week 295)
Population: The SS\_A consisted of all enrolled participants on adjunctive therapy who received at least 1 dose of study medication in the evaluation period. The SS\_M consisted of all enrolled participants on monotherapy who received at least 1 dose of study medication in the evaluation period.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period | 56.3 percentage of participants |
| Levetiracetam: Monotherapy | Percentage of Participants With Treatment-emergent SAEs During the Combined First and Second Period | 33.3 percentage of participants |
Secondary
Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period
A serious adverse event (SAE) is defined as any untoward medical occurrence at any dose that must meet 1 or more of the following criteria: Death; Life-threatening; Significant or persistent disability/incapacity; Congenital anomaly/birth defect (including that occurring in a fetus); Important medical event that, based upon appropriate medical judgment, may jeopardize the patient or participant and may require medical or surgical intervention to prevent 1 of the other outcomes listed in the definition of serious; Initial inpatient hospitalization or prolongation of hospitalization. The TEAEs were defined as those events that started on or after the date (and time) of first dose of study medication, or adverse events whose intensity worsened on or after the date (and time) of first dose of study medication.
Time frame: From Baseline (Week 0) to Visit 6 (up to Week 6)
Population: The SS\_A consisted of all enrolled participants on adjunctive therapy who received at least 1 dose of study medication in the evaluation period. The SS\_M consisted of all enrolled participants on monotherapy who received at least 1 dose of study medication in the evaluation period.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period | 9.4 percentage of participants |
| Levetiracetam: Monotherapy | Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the First Period | 0 percentage of participants |
Secondary
Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy
Percent difference in partial seizure frequency (PSF) per week at each Analysis Visit: {\[(Number of partial seizures per week at Baseline \[BL\]) - (Number of partial seizures per week at analysis visit X)\]/(Number of partial seizures per week at BL)}\*100. Positive value indicates reduction in PSF from BL. End of study (EOS)/early discontinuation visit (EDV) was based on last EDV and calculation of number of partial seizure per week were based on the period from the previous EDV visit. The mapping of seizure data to Analysis Visits was based on target dates of the visits. A seizure date after that of target date of an Analysis Visit n and up to that of target date of next Analysis Visit n+1 was mapped to the next Analysis Visit (n+1). Data for one participant assessed within study duration was mapped to Analysis Visit 35/Week 300 based on statistical plan.
Time frame: From Baseline (Week 0), Week 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, 288, 300, EOS/EDV (up to Week 295), and Safety follow-up (up to Week 295)
Population: The FAS\_A consisted of all participants in the SS\_A who had at least 1 post-Baseline efficacy assessment. Here, number of participants analyzed signifies participants who were evaluable for this outcome measure. Here, number analyzed signifies participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 8 | 35.53 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 10 | 59.39 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 15 | 60.29 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 18 | 82.74 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 21 | 80.33 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 24 | 88.44 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 12 | 50.90 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 36 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 96 | 99.57 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 156 | 99.76 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 228 | 97.12 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 27 | 93.84 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 30 | 98.05 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 48 | 98.70 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 60 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 72 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 84 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 108 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 120 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 132 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 144 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 168 | 99.74 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 180 | 99.02 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 192 | 99.76 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 204 | 97.94 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 216 | 96.58 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 240 | 96.36 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 252 | 91.12 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 264 | 96.91 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 276 | 96.40 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 288 | 96.14 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Week 300 | 89.7 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | EOS/EDV | 21.86 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Adjunctive Therapy | Safety Follow Up | 39.82 percent change |
Secondary
Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy
The percent difference in partial seizure frequency per week on monotherapy at Baseline and each analysis visit was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at analysis visit X)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on monotherapy. The maximum duration of study participation in monotherapy participants was shorter than in adjunctive therapy. Therefore, data at Week 288 and 300 is not reported for Monotherapy.
Time frame: From Baseline (Week 0), Week 2, 4, 6, 8, 10, 12, 15, 18, 21, 24, 27, 30, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, 156, 168, 180, 192, 204, 216, 228, 240, 252, 264, 276, and Safety follow-up (up to Week 295)
Population: The FAS\_M consisted of all participants in the SS\_M who had at least 1 post-Baseline efficacy assessment. Here, number analyzed signifies participants who were evaluable at specified time points.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 21 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 24 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 27 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 30 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 36 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 48 | 98.08 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 60 | 94.23 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 72 | 92.31 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 84 | 95.79 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 96 | 98.08 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 108 | 96.15 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 120 | 93.68 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 132 | 92.63 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 144 | 92.63 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 156 | 94.73 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 168 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 180 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 192 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 204 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 216 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 228 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 240 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 252 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 264 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 276 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Safety Follow Up | 100.0 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 6 | 51.10 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 2 | -51.87 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 4 | 4.88 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 8 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 10 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 12 | 76.92 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 15 | 100.00 percent change |
| Levetiracetam: Adjunctive Therapy | Percent Change From Baseline for Each Analysis Visit in Partial Seizure Frequency Per Week on Monotherapy | Week 18 | 91.58 percent change |
Secondary
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 4
The percent difference in partial seizure frequency per week at Baseline and Study Visit 4 (Week 2) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 4)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.
Time frame: From Baseline (Week 0) to Visit 4 (up to Week 2)
Population: The FAS\_A consisted of all participants in the SS\_A who had at least 1 post-Baseline efficacy assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 4 | 8.62 percent change |
Secondary
Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 5
The percent difference in partial seizure frequency per week at Baseline and Study Visit 5 (Week 4) was computed as: {\[(Number of partial seizures per week at Baseline) minus (Number of partial seizures per week at Study Visit 5)\] divided by (Number of partial seizures per week at Baseline)} multiplied by 100. A positive value in percent difference from Baseline indicates a reduction in partial seizure frequency from Baseline. Data of this outcome measure was analyzed and reported for participants on adjunctive therapy.
Time frame: From Baseline (Week 0) to Visit 5 (up to Week 4)
Population: The FAS\_A consisted of all participants in the SS\_A who had at least 1 post-Baseline efficacy assessment.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Levetiracetam: Adjunctive Therapy | Percent Change in Partial Seizure Frequency Per Week From Baseline to Visit 5 | 16.79 percent change |